In our naturalistic SATS study including ChEI-treated patients with mild-to-moderate AD, APOE ε4-carriers exhibited both a lower cognitive response after six months of treatment and poorer long-term outcome after three years. This evidence concerns the gene APOE and Alzheimer disease.